Suppression of inflammation and acquired immunity by IL-37

Immunological Reviews

Volumn 281, Issue 1, 2018, Pages 179-190

  Cavalli, Giulio ^a,b   Dinarello, Charles A ^b,c  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

IL 1 family; Inflammation; Metabolism; Regulatory cytokines; Toll like receptors

Indexed keywords

DRUG BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR TYPE 8; INTERLEUKIN 10; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 37; RECOMBINANT CYTOKINE; SMAD3 PROTEIN; UNCLASSIFIED DRUG; IL37 PROTEIN, HUMAN; INTERLEUKIN 1;

ADAPTIVE IMMUNITY; AGING; ANTIINFLAMMATORY ACTIVITY; AORTIC VALVE DISEASE; ARTICLE; CELL ENERGY; CELL METABOLISM; COMPUTER MODEL; CONCENTRATION (PARAMETERS); DENDRITIC CELL; DIMERIZATION; DRUG MECHANISM; DRUG RELEASE; EXPERIMENTAL COLITIS; GENE TRANSLOCATION; HUMAN; INFLAMMATION; LUNG ASPERGILLOSIS; MALIGNANT NEOPLASM; METABOLIC SYNDROME X; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; RHEUMATOID ARTHRITIS; SPINAL CORD INJURY; ANIMAL; AUTOIMMUNE DISEASE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; MOUSE; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANIMALS; AUTOIMMUNE DISEASES; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; INTERLEUKIN-1; MICE; SIGNAL TRANSDUCTION;

EID: 85038021614     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12605     Document Type: Article

References (73)

1. Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11:1014‐1022.
2. McNamee EN, Masterson JC, Jedlicka P, et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci USA. 2011;108:16711‐16716.
3. Yousif NG, Li J, Yousif F, et al. Expression of IL-37 in mouse protects the myocardium against ischemic injury via modulation of NF-κB activation. Circulation. 2011;124(Suppl 21):A8603.
4. Ballak DB, Li S, Van Diepen JA, et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Cytokine. 2013;63:245‐246.
5. Nold-Petry CA, Lo CY, Rudloff I, et al. IL-37 requires the receptors IL-18Ralpha and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction. Nat Immunol. 2015;16:354‐365.
6. Coll-Miro M, Francos-Quijorna I, Santos-Nogueira E, et al. Beneficial effects of IL-37 after spinal cord injury in mice. Proc Natl Acad Sci USA. 2016;113:1411‐1416.
7. Li S, Neff CP, Barber K, et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci USA. 2015;112:2497‐2502.
8. Moretti S, Bozza S, Oikonomou V, et al. IL-37 inhibits inflammasome activation and disease severity in murine aspergillosis. PLoS Pathog. 2014;10:e1004462.
9. Wu B, Meng K, Ji Q, et al. Interleukin-37 ameliorates myocar-dial ischaemia/reperfusion injury in mice. Clin Exp Immunol. 2014;176:438‐451.
10. Ye L, Ji L, Wen Z, et al. IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: Its correlation with disease activity. J Transl Med. 2014;12:69.
11. Lunding L, Webering S, Vock C, et al. IL-37 requires IL-18Ralpha and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice. Allergy. 2015;70:366‐373.
12. Cavalli G, Koenders M, Kalabokis V, et al. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford). 2016;55:2220‐2229.
13. Cavalli G, Justice JN, Boyle KE, et al. Interleukin 37 reverses the metabolic cost of inflammation, increases oxidative respiration, and improves exercise tolerance. Proc Natl Acad Sci USA. 2017;114:2313‐2318.
14. Luo Y, Cai X, Liu S, et al. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc Natl Acad Sci USA. 2014;111:15178‐15183.
15. Kumar S, McDonnell PC, Lehr R, et al. Identification and initial characterization of four novel members of the interleukin-1 family. J Biol Chem. 2000;275:10308‐10314.
16. Busfield SJ, Comrack CA, Yu G, et al. Identification and gene organization of three novel members of the IL-1 family on human chromosome 2. Genomics. 2000;66:213‐216.
17. Pan G, Risser P, Mao W, et al. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL- 1Rrp. Cytokine. 2001;13:1‐7.
18. Sharaf N, Nicklin MJ, di Giovine FS. Long-range DNA interactions at the IL-1/IL-36/IL-37 gene cluster (2q13) are induced by activation of monocytes. Cytokine. 2014;68:16‐22.
19. Newman TL, Tuzun E, Morrison VA, et al. A genome-wide survey of structural variation between human and chimpanzee. Genome Res. 2005;15:1344‐1356.
20. Bufler P, Gamboni-Robertson F, Azam T, Kim SH, Dinarello CA. Interleukin-1 homologues IL-1F7b and IL-18 contain functional mRNA instability elements within the coding region responsive to li-popolysaccharide. Biochem J. 2004;381:503‐510.
21. Zhao PW, Jiang WG, Wang L, Jiang ZY, Shan YX, Jiang YF. Plasma levels of IL-37 and correlation with TNF-alpha, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. PLoS ONE. 2014;9:e95346.
22. Southcombe JH, Redman CW, Sargent IL, Granne I. Interleukin-1 family cytokines and their regulatory proteins in normal pregnancy and pre-eclampsia. Clin Exp Immunol. 2015;181:480‐490.
23. Bulau AM, Nold MF, Li S, et al. Role of caspase-1 in nuclear translo-cation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. Proc Natl Acad Sci USA. 2014;111:2650‐2655.
24. Kumar S, Hanning CR, Brigham-Burke MR, et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processed by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine. 2002;18:61‐71.
25. Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem. 2011;286:42594‐42602.
26. Rudloff I, Cho SX, Lao JC, et al. Monocytes and dendritic cells are the primary sources of interleukin 37 in human immune cells. J Leukoc Biol. 2017;101:901‐911.
27. Bufler P, Azam T, Gamboni-Robertson F, et al. A complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity. Proc Natl Acad Sci USA. 2002;99:13723‐13728.
28. Tsutsumi N, Kimura T, Arita K, et al. The structural basis for receptor recognition of human interleukin-18. Nat Commun. 2014;5:5340.
29. Garlanda C, Riva F, Bonavita E, Mantovani A. Negative regulatory receptors of the IL-1 family. Semin Immunol. 2013;25:408‐415.
30. Garlanda C, Anders HJ, Mantovani A. TIR8/SIGIRR: An IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol. 2009;30:439‐446.
31. Gong J, Wei T, Stark RW, et al. Inhibition of Toll-like receptors TLR4 and 7 signaling pathways by SIGIRR: A computational approach. J Struct Biol. 2010;169:323‐330.
32. Garlanda C, Riva F, Bonavita E, Gentile S, Mantovani A. Decoys and regulatory “receptors” of the IL-1/Toll-like receptor superfamily. Front Immunol. 2013;4:180.
33. Qin J, Qian Y, Yao J, Grace C, Li X. SIGIRR inhibits interleukin-1 re-ceptor-and toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem. 2005;280:25233‐25241.
34. Garlanda C, Riva F, Polentarutti N, et al. Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family. Proc Natl Acad Sci USA. 2004;101:3522‐3526.
35. Barry J, Loh Z, Collison A, et al. Absence of Toll-IL-1 receptor 8/single immunoglobulin IL-1 receptor-related molecule reduces house dust mite-induced allergic airway inflammation in mice. Am J Respir Cell Mol Biol. 2013;49:481‐490.
36. Kadota C, Ishihara S, Aziz MM, et al. Down-regulation of single immunoglobulin interleukin-1R-related molecule (SIGIRR)/TIR8 expression in intestinal epithelial cells during inflammation. Clin Exp Immunol. 2010;162:348‐361.
37. Kimura T, Tsutsumi N, Arita K, et al. Purification, crystallization and preliminary X-ray crystallographic analysis of human IL-18 and its extracellular complexes. Acta Crystallogr F Struct Biol Commun. 2014;70:1351‐1356.
38. Nold-Petry CA, Nold MF, Nielsen JW, et al. Increased cytokine production in interleukin-18 receptor alpha-deficient cells is associated with dysregulation of suppressors of cytokine signaling. J Biol Chem. 2009;284:25900‐25911.
39. Xu WD, Zhao Y, Liu Y. Insights into IL-37, the role in autoimmune diseases. Autoimmun Rev. 2015;14:1170‐1175.
40. Girard C, Rech J, Brown M, et al. Elevated serum levels of free interleukin-18 in adult-onset Still’s disease. Rheumatology (Oxford). 2016;55:2237‐2247.
41. Novick D, Kim S-H, Fantuzzi G, Reznikov L, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity. 1999;10:127‐136.
42. Chudnovskiy A, Mortha A, Kana V, et al. Host-protozoan interactions protect from mucosal infections through activation of the inflammasome. Cell. 2016;167(444–456):e414.
43. Novick D, Schwartsburd B, Pinkus R, et al. A novel IL-18BP ELISA shows elevated serum il-18BP in sepsis and extensive decrease of free IL-18. Cytokine. 2001;14:334‐342.
44. Banda NK, Vondracek A, Kraus D, et al. Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J Immunol. 2003;170:2100‐2105.
45. Canna SW, de Jesus AA, Gouni S, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macro-phage activation syndrome. Nat Genet. 2014;46:1140‐1146.
46. Mazodier K, Marin V, Novick D, et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood. 2005;106:3483‐3489.
47. Tak PP, Bacchi M, Bertolino M. Pharmacokinetics of IL-18 binding protein in healthy volunteers and subjects with rheumatoid arthritis or plaque psoriasis. Eur J Drug Metab Pharmacokinet. 2006;31:109‐116.
48. Ellisdon AM, Nold-Petry CA, D’Andrea L, et al. Homodimerization attenuates the anti-inflammatory activity of interleukin-37. Sci Immunol. 2017;2:eaaj1548.
49. Sharma S, Kulk N, Nold MF, et al. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines. J Immunol. 2008;180:5477‐5482.
50. Cohen I, Rider P, Carmi Y, et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci USA. 2010;107:2574‐2579.
51. Carriere V, Roussel L, Ortega N, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 2007;104:282‐287.
52. Ross R, Grimmel J, Goedicke S, et al. Analysis of nuclear localization of interleukin-1 family cytokines by flow cytometry. J Immunol Methods. 2013;387:219‐227.
53. Grimsby S, Jaensson H, Dubrovska A, Lomnytska M, Hellman U, Souchelnytskyi S. Proteomics-based identification of proteins interacting with Smad3: SREBP-2 forms a complex with Smad3 and inhibits its transcriptional activity. FEBS Lett. 2004;577:93‐100.
54. Sakai N, Van Sweringen HL, Belizaire RM, et al. Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J Gastroenterol Hepatol. 2012;27:1609‐1616.
55. O’Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 2013;493:346‐355.
56. Stienstra R, van Diepen JA, Tack CJ, et al. Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci USA. 2011;108:15324‐15329.
57. Stienstra R, Joosten LA, Koenen T, et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 2011;12:593‐605.
58. Henry CJ, Casas-Selves M, Kim J, et al. Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors. J Clin Invest. 2015;125:4666‐4680.
59. Ye L, Jiang B, Deng J, et al. IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-triggering cytokine production and limiting Th17 cell proliferation. J Immunol. 2015;194:5110‐5119.
60. Zeng Q, Song R, Fullerton DA, et al. Interleukin-37 suppresses the osteogenic responses of human aortic valve interstitial cells in vitro and alleviates valve lesions in mice. Proc Natl Acad Sci USA. 2017;114:1631‐1636.
61. Luo Y, Liu S, Lee J, et al. IL-37, and inhibitor of innate and adaptive immunity, is elevated in the blood of melanoma patients. Pigment Cell Mel Res. 2013;26:951.
62. Shuai X, Wei-min L, Tong YL, Dong N, Sheng ZY, Yao YM. Expression of IL-37 contributes to the immunosuppressive property of human CD4 + CD25 + regulatory T cells. Sci Rep. 2015;5:14478.
63. Banchereau J, Pascual V, O’Garra A. From IL-2 to IL-37: The expanding spectrum of anti-inflammatory cytokines. Nat Immunol. 2012;13:925‐931.
64. Imaeda H, Takahashi K, Fujimoto T, et al. Epithelial expression of interleukin-37b in inflammatory bowel disease. Clin Exp Immunol. 2013;172:410‐416.
65. Weidlich S, Bulau A-M, Schwerd T, et al. Intestinal expression of the anti-inflammatory interleukin-1 family member IL-37 in pediatric inflammatory bowel disease. J Pediatr Gastro Nutr. 2014;59:e18‐e26.
66. Xia L, Shen H, Lu J. Elevated serum and synovial fluid levels of interleukin-37 in patients with rheumatoid arthritis: Attenuated the production of inflammatory cytokines. Cytokine. 2015;76:553‐557.
67. Pei B, Xu S, Liu T, Pan F, Xu J, Ding C. Associations of the IL-1F7 gene polymorphisms with rheumatoid arthritis in Chinese Han population. Int J Immunogenet. 2013;40:199‐203.
68. Højen JF, Rasmussen TA, Andersen KL, et al. Interleukin-37 expression is increased in chronic HIV-1-infected individuals and is associated with inflammation and the size of the total viral reservoir. Mol Med. 2015;21:337‐345.
69. Shi LP, He Y, Liu ZD. Correlation between single nucleotide polymor-phism of rs3811047 in IL-1 F7 gene and rheumatoid arthritis susceptibility among Han population in central plains of China. Asian Pac J Trop Med. 2013;6:73‐75.
70. Yin D, Naji DH, Xia Y, et al. Genomic variant in IL-37 confers a significant risk of coronary artery disease. Sci Rep. 2017;7:42175.
71. Kang B, Cheng S, Peng J, Yan J, Zhang S. Interleukin-37 gene variants segregated anciently coexist during hominid evolution. Eur J Hum Genet. 2015;23:1392‐1398.
72. Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford). 2015;54:2134‐2144.
73. Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2004;43:III17‐III23.